297756
Minimizing Dual-Eilgible Beneficiaries Out-of-Pocket Prescription Drug Costs: A Paradigm Shift
Methods: We assisted 151 dual-eligible beneficiaries with their Part D plan in Northern/Central California in fall 2013. In addition to determining the lowest cost Part D plan, we examined if beneficiaries’ out-of-pocket costs could be further reduced by selecting an alternative plan under which their medication(s) was non-formulary but covered by Medi-Cal.
Results: Dual-eligible beneficiaries could annually save an average (SD) of $1174 ($3286) through Part D plan optimization. In 44 (27.8%) instances, beneficiaries could save additional money (Mean + SD: $107+281) through Part D and Medi-Cal formulary optimization. Each time, the lowest cost plan was a benchmark plan.
Conclusions: Dual-eligible beneficiaries have incomes <100% of the Federal Poverty Line. Research has shown that as out-of-pocket costs increase so too does medication non-adherence. Aside from Part D plan optimization, we identified a novel approach that can be utilized to help further lower out-of-pocket prescription drug costs in the vulnerable dual-eligible beneficiary population.
Learning Areas:
Public health or related laws, regulations, standards, or guidelinesPublic health or related public policy
Systems thinking models (conceptual and theoretical models), applications related to public health
Learning Objectives:
Describe a novel approach to assisting dual-Eligible (Medicare + Medicaid)beneficiaries with their out-of-pocket prescription drug costs.
Demonstrate the absolute and relative potential cost-savings opportunities resulting from a change in the way that dual-eligible beneficiaries are assisted with the Part D plan.
Keyword(s): Policy/Policy Development, Health Care Costs
Qualified on the content I am responsible for because: I have worked with Medicare beneficiaries helping them optimize their Part D benefit for the last 7 years. In that time I have presented over 60 posters and podium talks at national/international meetings on various aspects of the Part D benefit. I have also published extensively in this arena.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.